New drug aims to turn immune system against stomach cancer
NCT ID NCT03505320
Summary
This study is testing an experimental drug called zolbetuximab for people with advanced stomach or gastroesophageal junction cancer. The drug targets a specific protein (CLDN18.2) found on many of these tumors, aiming to flag them for the body's own immune system to attack. Researchers are testing the drug by itself and in combination with standard chemotherapy and other immunotherapy drugs to see which approach works best.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mass General / North Shore Can
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Site FR33001
Brest, France
-
Site FR33002
Poitiers, Nouvelle-Aquitaine, 86021, France
-
Site FR33003
Pessac, Nouvelle-Aquitaine, 33604, France
-
Site FR33004
Paris, 75015, France
-
Site IT39002
Naples, Italy
-
Site IT39003
Pisa, Italy
-
Site IT39004
Padua, Italy
-
Site IT39005
Milan, Italy
-
Site JP81001
Chiba, Japan
-
Site JP81002
Tokyo, Japan
-
Site JP81003
Tokyo, Japan
-
Site KR82001
Seoul, South Korea
-
Site KR82002
Seongnam-si, South Korea
-
Site TW88601
Taichung, Taiwan
-
Site TW88602
Tainan, 70403, Taiwan
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
UCLA Medical Center
Santa Monica, California, 90404, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.